Spyre Therapeutics, Inc. participates in key Boston investor event

Spyre Therapeutics, Inc. participates in key Boston investor event
Spyre Therapeutics to join Boston forum

Spyre Therapeutics, Inc. will take part in the Leerink Partners Therapeutics Forum scheduled for July 14 in Boston, Massachusetts.

Company representatives plan to host investor meetings throughout the forum, aiming to engage with partners and stakeholders. The event serves as a significant opportunity for Spyre Therapeutics, Inc. to connect with the investment community and highlight its ongoing projects. Details about agenda specifics have not yet been disclosed.

Spyre Therapeutics, Inc. previously reported strong Phase 2 data for its SPY002 program in ulcerative colitis, achieving a 10.7-point reduction in RHI score and 33 percent remission rates, according to company disclosures. The data release highlighted progress in the company’s development pipeline. Investors are likely to watch for additional updates on clinical milestones at the upcoming event.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.